Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Can the Albumin/High Sensitive C-reactive Protein Ratio be Utilized for Predicting Gestational Diabetes Mellitus Diagnosis or the Adverse Outcomes

NCT06761053 is registered in ClinicalTrials.gov with ALI BAHADIRLI as lead sponsor.

NCT NCT06761053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06761053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Can the Albumin/High Sensitive C-reactive Protein Ratio be Utilized for Predicting Gestational Diabetes Mellitus Diagnosis or the Adverse Outcomes
Lead sponsor
ALI BAHADIRLI
Phase
Not applicable
Overall status
Completed
Start date
February 3, 2021
Completion date
July 3, 2022
Enrollment
146 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gestational diabetes mellitus in pregnancy